Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

VNDA / Vanda Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC - 3G/A (Passive Investment)

2018-02-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Vanda Pharmaceuticals Inc. (Name of Issuer)     Common Stock, $0.001 par value per share (Title of Class of Securities)     921659108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X] Rul

VNDA / Vanda Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G (Passive Investment)

2018-02-16 sec.gov
SC 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)*     Vanda Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 921659108 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)   * T

VNDA / Vanda Pharmaceuticals, Inc. / MACQUARIE GROUP LTD - SC 13G (Passive Investment)

2018-02-15 sec.gov
SC 13G     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 0)*     Vanda Pharmaceuticals Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 921659108 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)   * T

VNDA / Vanda Pharmaceuticals, Inc. / GREAT POINT PARTNERS LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 1)*   Vanda Pharmaceuticals Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   921659108 (CUSIP Number)   December 31, 2017 (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b)     o Rule 13d-1(c)     o Rule 13d-1(d)   *Th

VNDA / Vanda Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 1)*     Vanda Pharmaceuticals Inc. (Name of Issuer)     Common Stock, $0.001 par value per share (Title of Class of Securities)     921659108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [_] Rule 13d-1(b)   [X] Rul

VNDA / Vanda Pharmaceuticals, Inc. 8-K (Current Report)

2018-02-15 sec.gov
8-K     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2018     VANDA PHARMACEUTICALS INC. (Exact name of Registrant as specified in its charter)     Delaware (State or other jurisdiction of incorporation)   001-34186   03-0491827 (Commission File No.

VNDA / Vanda Pharmaceuticals, Inc. / GREAT POINT PARTNERS LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A   Under the Securities Exchange Act of 1934 (Amendment No. 1)*   Vanda Pharmaceuticals Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   921659108 (CUSIP Number)   December 31, 2017 (Date of Event which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   x Rule 13d-1(b)     o Rule 13d-1(c)     o Rule 13d-1(d)   *Th

VNDA / Vanda Pharmaceuticals, Inc. FORM 10-K (Annual Report)

2018-02-15 sec.gov
Form 10-K Table of Contents     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     Form 10-K       ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017   ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186     VANDA PHARMACEUTICALS INC.

VNDA / Vanda Pharmaceuticals, Inc. / Palo Alto Investors, LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)     Vanda Pharmaceuticals, Inc. (Name of Issuer)     Common Stock (Title of Class of Securities)     921659108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   [ X ] Rule 13d-1(b)   [ ] Rule 13d-1(c)   [ ] Rule 13d-

VNDA / Vanda Pharmaceuticals, Inc. / Palo Alto Investors, LLC - 3G/A (Passive Investment)

2018-02-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)     Vanda Pharmaceuticals, Inc. (Name of Issuer)     Common Stock (Title of Class of Securities)     921659108 (CUSIP Number)     December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pursuant to which this Schedule is filed:   [ X ] Rule 13d-1(b)   [ ] Rule 13d-1(c)   [ ] Rule 13d-

Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q4 2017 Results - Earnings Call Transcript

2018-02-15 seekingalpha
Welcome to the Fourth Quarter 2017 Vanda Pharmaceuticals Incorporated Earnings Conference Call. My name is Hilda and I will be your operator for today. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded. (1-0)

VNDA / Vanda Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #1 (Passive Investment)

2018-02-14 sec.gov
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Vanda Pharmaceuticals Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per Share (CUSIP Number) 921659108 (Date of Event Which Requires Filing of this Statement) Decem

VNDA / Vanda Pharmaceuticals, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G/A, AMENDMENT #1 (Passive Investment)

2018-02-14 sec.gov
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Vanda Pharmaceuticals Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per Share (CUSIP Number) 921659108 (Date of Event Which Requires Filing of this Statement) Decem

VNDA / Vanda Pharmaceuticals, Inc. / Flynn James E - 3G/A (Passive Investment)

2018-02-14 sec.gov
  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G (Rule 13d-102)   INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)   (Amendment No. 5) *   Vanda Pharmaceuticals Inc. (Name of Issuer)   Common Stock (Title of Class of Securities)   921659108 (CUSIP Number)   December 31, 2017 (Date of Event Which Requires Filing of this Statement)   Check the appropriate box to designate the rule pu


CUSIP: 921659108